HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Early and transient sodium-hydrogen exchanger isoform 1 inhibition attenuates subsequent cardiac hypertrophy and heart failure following coronary artery ligation.

Abstract
Na(+)/H(+) exchanger 1 (NHE-1) inhibition attenuates the hypertrophic response and heart failure in various experimental models. As the hypertrophic program is rapidly initiated following insult, we investigated whether early and transient administration of a NHE-1 inhibitor will exert salutary effects on cardiomyocyte hypertrophy or heart failure using both in vitro and in vivo approaches. Neonatal cardiomyocytes were treated with the novel, potent, and highly specific NHE-1 inhibitor BIX (N-[4-(1-acetyl-piperidin-4-yl)-3-trifluoromethyl-benzoyl]-guanidine; 100 nM) for 1 hour in the presence of 10 µM phenylephrine, after which the cells were maintained for a further 23 hours in the absence of NHE-1 inhibition. One-hour treatment with the NHE-1 inhibitor prevented phenylephrine-induced hypertrophy, which was associated with prevention of activation of calcineurin, a key component of the hypertrophic process. Experiments were then performed in rats subjected to coronary artery ligation, in which the NHE-1 inhibitor was administered immediately after infarction for a 1-week period followed by a further 5 weeks of sustained coronary artery occlusion in the absence of drug treatment. This approach significantly attenuated left ventricular hypertrophy and improved both left ventricular systolic and diastolic dysfunction, which was also associated with inhibition of calcineurin activation. Our findings indicate that early and transient administration of an NHE-1 inhibitor bestows subsequent inhibition of cardiomyocyte hypertrophy in culture as well as cardiac hypertrophy and heart failure in vivo, suggesting a critical early NHE-1-dependent initiation of the hypertrophic program. The study also suggests a preconditioning-like phenomenon in preventing hypertrophy and heart failure by early and transient NHE-1 inhibition.
AuthorsAna Kilić, Cathy X Huang, Venkatesh Rajapurohitam, Jeffrey B Madwed, Morris Karmazyn
JournalThe Journal of pharmacology and experimental therapeutics (J Pharmacol Exp Ther) Vol. 351 Issue 3 Pg. 492-9 (Dec 2014) ISSN: 1521-0103 [Electronic] United States
PMID25216745 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2014 by The American Society for Pharmacology and Experimental Therapeutics.
Chemical References
  • Piperidines
  • Protein Isoforms
  • Sodium-Hydrogen Exchangers
  • growth factor-activatable Na-H exchanger NHE-1
Topics
  • Animals
  • Animals, Newborn
  • Cardiomegaly (metabolism, pathology, prevention & control)
  • Cells, Cultured
  • Coronary Vessels (drug effects, metabolism, pathology)
  • Heart Failure (metabolism, pathology, prevention & control)
  • Ligation (adverse effects)
  • Myocytes, Cardiac (drug effects, metabolism, pathology)
  • Piperidines (chemistry, pharmacology, therapeutic use)
  • Protein Isoforms (antagonists & inhibitors, metabolism)
  • Rats
  • Rats, Sprague-Dawley
  • Sodium-Hydrogen Exchangers (antagonists & inhibitors, metabolism)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: